Tergus Pharma, LLC Announces Addition of Key Executive Management Positions
Seasoned Executives, James Wysocki and Alan Burns Join the Company
DURHAM, N.C., Dec. 16, 2019 /PRNewswire-PRWeb/ -- Tergus Pharma, the leading topical contract development and manufacturing organization (CDMO) with proven expertise in Topical Formulations, announces that it filled two key leadership positions with the appointment of executives James Wysocki as Chief Financial Officer (CFO) and Alan Burns as Vice-President of Quality and Regulatory Compliance.
Mr. Wysocki is an accomplished Financial leader with more than 20 years of experience in the medical device and pharmaceutical industries. His extensive divisional pharmaceutical / biotech / medical device experience is in addition to his 6 years of public accounting / auditing and 3 years of Corporate SEC reporting.
Mr. Wysocki held the Controller title at Pfizer where he was responsible for divisions with $9B in revenue. He then went on to become the Head of Finance with Novartis Vaccines, where he led the financial start-up of a $1B investment in a US Government pandemic site. It is this type of experience Tergus has been looking for to fill the Chief Financial Officer position as the Company moves into the Topical Contract Manufacturing space.
Mr. Burns has over 25 years of Quality and Compliance experience with increasing levels of responsibility in large pharmaceutical companies such as Abbott Laboratories, Eli Lilly, Bayer HealthCare and Purdue Pharma. His experience includes the management of both domestic and international organizations, including the buildout and startup of new manufacturing facilities, as well as in-depth interaction with numerous regulatory agencies around the world. Mr. Burns' experience and education make him an ideal choice for the role at Tergus Pharma.
"We are thrilled to have Jim and Alan join our Team" said Dr. Vijendra Nalamothu, Chairman and CEO of Tergus Pharma. "Jim's ability to clarify difficult and complex financial analyses helps him communicate effectively to non-financial audiences which aids in understanding and collaboration. Whereas Alan's experience across both development and commercial aspects of the industry, coupled with his extensive work with regulatory agencies, will serve us well as we expand our business model into commercial manufacturing. Both Jim and Alan are excellent fits for the Tergus organization."
Earlier this year, Tergus Pharma, LLC announced its plans for expansion, including late-phase and commercial manufacturing—acquiring a new 100,000-square-foot process development and cGMP manufacturing facility in the RTP area of North Carolina. To learn more or schedule an appointment, contact us at [email protected] or call 919-908-0564.
SOURCE Tergus Pharma
Share this article